Skip to main
BOLD
BOLD logo

BOLD Stock Forecast & Price Target

BOLD Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Boundless Bio Inc is positioned favorably within the oncology market due to its innovative approach in targeting extrachromosomal DNA (ecDNA), addressing a critical unmet need in patients with oncogene-amplified tumors. The company's lead candidate, BBI-355, demonstrates a promising toxicity-mitigated dosing strategy combined with the potential for synergistic effects, suggesting enhanced efficacy for cancer treatments. Additionally, ongoing development efforts in the kinesin targeting space indicate a shift towards precision therapies, further bolstering the company’s future growth prospects and potential upside in its valuation.

Bears say

The financial outlook for Boundless Bio Inc. is negative due to several fundamental concerns regarding its lead candidate, BBI-355. The company faces risks such as potential delays in clinical development, negative clinical data impacting the therapeutic window, and the possibility of failing to gain regulatory approval, all of which could significantly hinder its progress. Additionally, concerns about slower-than-anticipated commercial uptake and the risk of medium- to long-term dilution further exacerbate the unfavorable financial assessment of the company's stock.

BOLD has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boundless Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boundless Bio Inc (BOLD) Forecast

Analysts have given BOLD a Buy based on their latest research and market trends.

According to 2 analysts, BOLD has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boundless Bio Inc (BOLD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.